Catecholaminergic polymorphic ventricular tachycardia: MedlinePlus Genetics (2023)

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a condition characterized by an abnormal heart rhythm (arrhythmia). As the heart rate increases in response to physical activity or emotional stress, it can trigger an abnormally fast heartbeat called ventricular tachycardia. Episodes of ventricular tachycardia can cause light-headedness, dizziness, and fainting (syncope). In people with CPVT, these episodes typically begin in childhood.

If CPVT is not recognized and treated, an episode of ventricular tachycardia may cause the heart to stop beating (cardiac arrest), leading to sudden death. Researchers suspect that CPVT may be a significant cause of sudden death in children and young adults without recognized heart abnormalities.

CPVT most commonly results from mutations in two genes, RYR2 and CASQ2. RYR2 gene mutations cause about half of all cases, while mutations in the CASQ2 gene account for up to 5 percent of cases. Mutations in other genes are rare causes of the condition.

The RYR2 and CASQ2 genes provide instructions for making proteins that help maintain a regular heartbeat. For the heart to beat normally, heart muscle cells called myocytes must tense (contract) and relax in a coordinated way. Both the RYR2 and CASQ2 proteins are involved in the movement of calcium within myocytes, which is critical for the regular contraction of these cells.

Mutations in either the RYR2 or CASQ2 gene disrupt the handling of calcium within myocytes, which interferes with the coordination of contraction and relaxation of the heart, particularly during exercise or emotional stress. Impaired calcium regulation in the heart can lead to ventricular tachycardia in people with CPVT.

Similarly, other genes involved in CPVT play roles in calcium regulation in myocytes. Mutations in these genes also disrupt the normal movement of calcium inside these cells, impairing the coordination of heart beats.

Learn more about the genes associated with Catecholaminergic polymorphic ventricular tachycardia

• CASQ2
• RYR2

Additional Information from NCBI Gene:

• CALM1
• CALM2
• CALM3
• TECRL

When CPVT results from mutations in the RYR2 gene, it follows an autosomal dominant inheritance pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In about half of cases, an affected person inherits an RYR2 gene mutation from one affected parent. The remaining cases result from new (de novo) mutations in the RYR2 gene that occur during the formation of reproductive cells (eggs or sperm) in an affected individual's parent or in early embryonic development. These cases occur in people with no history of the disorder in their family.

When CPVT is caused by mutations in the CASQ2 gene, the condition almost always has an autosomal recessive pattern of inheritance. Autosomal recessive inheritance means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition. Very rarely, CASQ2-related CPVT may follow an autosomal dominant pattern of inheritance.

When caused by mutations in other genes, CPVT can be inherited in an autosomal dominant or autosomal recessive pattern.

Genetic Testing Information

• Genetic Testing Registry: Catecholaminergic polymorphic ventricular tachycardia
• Genetic Testing Registry: Ventricular tachycardia, catecholaminergic polymorphic, 2

Genetic and Rare Diseases Information Center

• Catecholaminergic polymorphic ventricular tachycardia

Patient Support and Advocacy Resources

• Disease InfoSearch
• National Organization for Rare Disorders (NORD)

Research Studies from ClinicalTrials.gov

• ClinicalTrials.gov

Catalog of Genes and Diseases from OMIM

• VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1, WITH OR WITHOUT ATRIAL DYSFUNCTION AND/OR DILATED CARDIOMYOPATHY
• VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2

Scientific Articles on PubMed

• PubMed

• Crotti L, Spazzolini C, Tester DJ, Ghidoni A, Baruteau AE, Beckmann BM, BehrER, Bennett JS, Bezzina CR, Bhuiyan ZA, Celiker A, Cerrone M, Dagradi F, DeFerrari GM, Etheridge SP, Fatah M, Garcia-Pavia P, Al-Ghamdi S, Hamilton RM,Al-Hassnan ZN, Horie M, Jimenez-Jaimez J, Kanter RJ, Kaski JP, Kotta MC,Lahrouchi N, Makita N, Norrish G, Odland HH, Ohno S, Papagiannis J, Parati G,Sekarski N, Tveten K, Vatta M, Webster G, Wilde AAM, Wojciak J, George AL,Ackerman MJ, Schwartz PJ. Calmodulin mutations and life-threatening cardiacarrhythmias: insights from the International Calmodulinopathy Registry. Eur HeartJ. 2019 Sep 14;40(35):2964-2975. doi: 10.1093/eurheartj/ehz311. Citation on PubMed or Free article on PubMed Central
• Gomez-Hurtado N, Boczek NJ, Kryshtal DO, Johnson CN, Sun J, Nitu FR, CorneaRL, Chazin WJ, Calvert ML, Tester DJ, Ackerman MJ, Knollmann BC. NovelCPVT-Associated Calmodulin Mutation in CALM3 (CALM3-A103V) ActivatesArrhythmogenic Ca Waves and Sparks. Circ Arrhythm Electrophysiol. 2016Aug;9(8):10.1161/CIRCEP.116.004161 e004161. doi: 10.1161/CIRCEP.116.004161. Citation on PubMed or Free article on PubMed Central
• Leenhardt A, Denjoy I, Guicheney P. Catecholaminergic polymorphic ventriculartachycardia. Circ Arrhythm Electrophysiol. 2012 Oct;5(5):1044-52. doi:10.1161/CIRCEP.111.962027. Epub 2012 Sep 27. No abstract available. Citation on PubMed
• Lieve KV, van der Werf C, Wilde AA. Catecholaminergic Polymorphic VentricularTachycardia. Circ J. 2016 May 25;80(6):1285-91. doi: 10.1253/circj.CJ-16-0326.Epub 2016 May 13. Citation on PubMed
• Moscu-Gregor A, Marschall C, Muntjes C, Schonecker A, Schuessler-Hahn F,Hohendanner F, Parwani AS, Boldt LH, Ott CE, Bennewiz A, Paul T, Krause U, RostI. Novel variants in TECRL cause recessive inherited CPVT type 3 with severe andvariable clinical symptoms. J Cardiovasc Electrophysiol. 2020Jun;31(6):1527-1535. doi: 10.1111/jce.14446. Epub 2020 Mar 22. Citation on PubMed
• Napolitano C, Mazzanti A, Bloise R, Priori SG. Catecholaminergic PolymorphicVentricular Tachycardia. 2004 Oct 14 [updated 2022 Jun 23]. In: Adam MP, MirzaaGM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors.GeneReviews(R) [Internet]. Seattle (WA): University of Washington,Seattle; 1993-2023. Available from http://www.ncbi.nlm.nih.gov/books/NBK1289/ Citation on PubMed
• Nyegaard M, Overgaard MT, Sondergaard MT, Vranas M, Behr ER, Hildebrandt LL,Lund J, Hedley PL, Camm AJ, Wettrell G, Fosdal I, Christiansen M, Borglum AD.Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death.Am J Hum Genet. 2012 Oct 5;91(4):703-12. doi: 10.1016/j.ajhg.2012.08.015. Citation on PubMed or Free article on PubMed Central
• Obeyesekere MN, Sy RW, Leong-Sit P, Gula LJ, Yee R, Skanes AC, Klein GJ, KrahnAD. Treatment of asymptomatic catecholaminergic polymorphic ventriculartachycardia. Future Cardiol. 2012 May;8(3):439-50. doi: 10.2217/fca.12.12. Citation on PubMed
• Pflaumer A, Davis AM. Guidelines for the diagnosis and management ofCatecholaminergic Polymorphic Ventricular Tachycardia. Heart Lung Circ. 2012Feb;21(2):96-100. doi: 10.1016/j.hlc.2011.10.008. Epub 2011 Nov 25. Citation on PubMed
• Refaat MM, Hassanieh S, Scheinman M. Catecholaminergic Polymorphic VentricularTachycardia. Card Electrophysiol Clin. 2016 Mar;8(1):233-7. doi:10.1016/j.ccep.2015.10.035. Citation on PubMed
• Roston TM, Cunningham TC, Sanatani S. Advances in the diagnosis and treatmentof catecholaminergic polymorphic ventricular tachycardia. Cardiol Young. 2017Jan;27(S1):S49-S56. doi: 10.1017/S1047951116002237. Citation on PubMed
• Roston TM, Van Petegem F, Sanatani S. Catecholaminergic polymorphicventricular tachycardia: a model for genotype-specific therapy. Curr OpinCardiol. 2017 Jan;32(1):78-85. doi: 10.1097/HCO.0000000000000360. Citation on PubMed
• Roux-Buisson N, Cacheux M, Fourest-Lieuvin A, Fauconnier J, Brocard J, DenjoyI, Durand P, Guicheney P, Kyndt F, Leenhardt A, Le Marec H, Lucet V, Mabo P,Probst V, Monnier N, Ray PF, Santoni E, Tremeaux P, Lacampagne A, Faure J,Lunardi J, Marty I. Absence of triadin, a protein of the calcium release complex,is responsible for cardiac arrhythmia with sudden death in human. Hum Mol Genet.2012 Jun 15;21(12):2759-67. doi: 10.1093/hmg/dds104. Epub 2012 Mar 14. Citation on PubMed or Free article on PubMed Central
• van der Werf C, Wilde AA. Catecholaminergic polymorphic ventriculartachycardia: from bench to bedside. Heart. 2013 Apr;99(7):497-504. doi:10.1136/heartjnl-2012-302033. Epub 2013 Feb 6. No abstract available. Citation on PubMed
• van der Werf C, Zwinderman AH, Wilde AA. Therapeutic approach for patientswith catecholaminergic polymorphic ventricular tachycardia: state of the art andfuture developments. Europace. 2012 Feb;14(2):175-83. doi:10.1093/europace/eur277. Epub 2011 Sep 4. Erratum In: Europace. 2012Dec;14(12):1810. Citation on PubMed
• Wall JJ, Iyer RV. Catecholaminergic Polymorphic Ventricular Tachycardia.Pediatr Emerg Care. 2017 Jun;33(6):427-431. doi: 10.1097/PEC.0000000000001156. Citation on PubMed
• Wleklinski MJ, Kannankeril PJ, Knollmann BC. Molecular and tissue mechanismsof catecholaminergic polymorphic ventricular tachycardia. J Physiol. 2020Jul;598(14):2817-2834. doi: 10.1113/JP276757. Epub 2020 Apr 27. Citation on PubMed
• Ylanen K, Poutanen T, Hiippala A, Swan H, Korppi M. Catecholaminergicpolymorphic ventricular tachycardia. Eur J Pediatr. 2010 May;169(5):535-42. doi:10.1007/s00431-010-1154-2. Epub 2010 Feb 9. Citation on PubMed